Have a feature idea you'd love to see implemented?
Let us know!
DMAC DiaMedica Therapeutics Inc
Price (delayed)
$4.335
Market cap
$185.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.53
Enterprise value
$171.63M
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.
Highlights
The company's EPS rose by 15% YoY and by 5% QoQ
DiaMedica Therapeutics's equity has increased by 15% from the previous quarter but it has decreased by 11% YoY
DMAC's debt is down by 12% year-on-year but it is up by 2.1% since the previous quarter
The net income has contracted by 21% YoY and by 3.2% from the previous quarter
The quick ratio has contracted by 15% YoY
Key stats
What are the main financial stats of DMAC
Market
Valuations
Earnings
Shares outstanding
42.75M
Market cap
$185.31M
Enterprise value
$171.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.85M
EBITDA
-$19.74M
Free cash flow
-$19.8M
Per share
Balance sheet
Liquidity
EPS
-$0.53
Free cash flow per share
-$0.52
Book value per share
$1.41
Revenue per share
$0
TBVPS
$1.49
Total assets
$56.79M
Total liabilities
$3.38M
Debt
$388,000
Equity
$53.42M
Working capital
$51.93M
Debt to equity
0.01
Current ratio
17.82
Quick ratio
17.63
Net debt/EBITDA
0.69
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.4%
Return on equity
-38.5%
Return on invested capital
-42.6%
Return on capital employed
-37%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DMAC stock price
How has the DiaMedica Therapeutics stock price performed over time
Intraday
-1.03%
1 week
1.05%
1 month
7.57%
1 year
91.81%
YTD
52.64%
QTD
3.46%
Financial performance
How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.38M
Net income
-$19.89M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 29% YoY and by 4.2% from the previous quarter
The net income has contracted by 21% YoY and by 3.2% from the previous quarter
Growth
What is DiaMedica Therapeutics's growth rate over time
Valuation
What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
3.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 15% YoY and by 5% QoQ
The stock's price to book (P/B) is 47% more than its last 4 quarters average of 2.1 but 3.8% less than its 5-year quarterly average of 3.2
DiaMedica Therapeutics's equity has increased by 15% from the previous quarter but it has decreased by 11% YoY
Efficiency
How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has decreased by 11% QoQ but it has increased by 8% YoY
DiaMedica Therapeutics's return on equity has increased by 10% YoY but it has decreased by 6% QoQ
The return on assets is up by 9% year-on-year but it has declined by 6% since the previous quarter
Dividends
What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DMAC.
Financial health
How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has increased by 46% YoY and by 16% from the previous quarter
The current ratio has decreased by 16% YoY
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has increased by 15% from the previous quarter but it has decreased by 11% YoY
DMAC's debt is down by 12% year-on-year but it is up by 2.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.